Compare RNA & TCGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | TCGX |
|---|---|---|
| Founded | 2025 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 113.4M |
| IPO Year | 2025 | 2026 |
| Metric | RNA | TCGX |
|---|---|---|
| Price | $8.28 | $10.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 205.4K | ★ 230.3K |
| Earning Date | 08-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.49 | $9.90 |
| 52 Week High | $73.06 | $18.91 |
| Indicator | RNA | TCGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 30.04 |
| Support Level | $7.56 | $9.90 |
| Resistance Level | $8.50 | $15.00 |
| Average True Range (ATR) | 0.35 | 0.68 |
| MACD | 0.17 | -0.22 |
| Stochastic Oscillator | 54.46 | 3.39 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
TCGX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.